Medpace Announces the Addition of Dan Weng, MD, PhD, MA as Vice President, ROW
News Jan 27, 2011
Medpace, Inc. has announced the addition of Dan Weng, MD, PhD, MA as Vice President, Rest of World (ROW) with responsibility for Asia, Pacific Rim, Latin America, and South Africa. Dr. Weng, an experienced clinical development professional, will be charged with driving global growth for Medpace in emerging markets.
Emerging markets represent the fastest growing segment for drug development and clinical trials. The addition of Dr. Weng, along with existing Medpace clinical teams, will allow Medpace to provide deeper expertise in global development services for sponsors needing on-the-ground services in global markets.
"We are very pleased to have Dr. Weng join us. Dr. Weng enhances Medpace's expertise in managing multi-national clinical trials in various therapeutic areas," said August Troendle, MD, President and CEO, Medpace. "His skill in managing global teams such as data services, regulatory, medical and safety, in addition to clinical operations adds to the overall capabilities of the Medpace group."
"I am very happy to join the Medpace team. Medpace has a reputation for great scientific process, clinical expertise, quality focus, and global capacity with local excellence in the markets they serve," said Dr. Weng. "I am confident that Medpace emerging markets will continue to develop local staffs to offer our sponsors new services on a global platform over the next few years."
Dr. Dan Weng brings to the Medpace management team over twenty five years of clinical experience, with seventeen years from executive positions with various clinical research organizations. Dr. Weng's extensive work in Asia, Pacific Rim, Latin America, and South Africa add to the global reach of the Medpace group.
Dr. Weng has held positions of increasing responsibility, including Executive Vice President, Emerging Markets over Rest of World. He has also served as a research fellow at Harvard Medical School and the University of California working on cardiovascular clinical trial protocol design, implementation, and review.
Dr. Weng received his Doctor of Medicine degree from Tongji Medical University in China and his undergraduate diploma in human psychology from the Psychology Institute of Sino-Academy of Sciences. Dr. Weng also received his Master of Arts in Healthy Planning, Policy, and Management from Leeds University in the United Kingdom in addition to being a PhD candidate in bioengineering from Strathclyde University in Glasgow, United Kingdom.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE